GlassScriptPhysician profile
Sanju A Varghese
NPI 1780629956
$57,513.74
in general payments reported to CMS, 2019-2025
39 companies · $4,741 in 2025
The $4,741 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,464 · 2020: $10K · 2021: $9,856 · 2022: $6,861 · 2023: $18K · 2024: $6,094 · 2025: $4,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $3,772 · Consulting Fee: $1,600 · Travel and Lodging: $1,248 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,050.00 |
| Food and Beverage | $3,772.31 |
| Consulting Fee | $1,600.00 |
| Travel and Lodging | $1,248.02 |
| Education | $316.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $50,459.58 | 2019-2025 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $830.73 | 2019-2025 | |
| Amgen INC. | $815.07 | 2019-2025 | Tavneos, Krystexxa, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $448.99 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $360.08 | 2020-2024 | Acthar |
| Akebia Therapeutics INC | $334.68 | 2019-2025 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $296.26 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $274.30 | 2019-2025 | Jynarque, Voyxact |
| Alexion Pharmaceuticals, INC. | $269.22 | 2019-2024 | Ultomiris |
| Vifor Pharma, INC. | $261.21 | 2019-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $255.48 | 2019-2025 | Velphoro, Velphoro |
| Daiichi Sankyo INC. | $234.48 | 2019-2023 | Injectafer |
| Abbvie INC. | $212.37 | 2021-2023 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $207.23 | 2023-2024 | Ozempic, Rybelsus |
| Ardelyx, INC. | $202.79 | 2024-2025 | Ibsrela |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanju Varghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.